Loading
Regulation of Appetite and Obesity · Journal article
npj Science of Food · August 8, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a preclinical study in diet-induced obese mice showing that lupin protein hydrolysate (LPH) reduces body and liver weight, attenuates hepatic steatosis, and enhances antioxidant capacity via upregulation of Nrf2 and antioxidant enzymes. In silico modelling identified candidate bioactive peptides predicted to target the KEAP1–NRF2 axis, but neither human efficacy nor clinical translation is demonstrated.
Preclinical intervention study in diet-induced obese mouse model. Diet-induced obese mice; model of metabolic dysfunction–associated steatotic liver disease (MASLD).. Intervention: Lupinus angustifolius protein hydrolysates (LPH) supplementation.
LPH supplementation significantly reduced body and liver weight in diet-induced obese mice LPH attenuated hepatic steatosis and normalized lipid accumulation and triglyceride levels LPH upregulated Nrf2 and increased SOD, GPx, and CAT antioxidant enzyme activities
No human clinical outcome data; efficacy and safety in humans unknown
These preclinical findings suggest a plausible mechanism by which lupin protein hydrolysate may mitigate MASLD through NRF2-dependent antioxidant pathways. However, no human efficacy data, optimal dosing, or safety profile are provided; clinical translation requires formal human trials.
Animal model study with mechanistic endpoints and computational prediction of bioactive peptides; no clinical efficacy data, human trials, or validated therapeutic dosing in the source.
As stated by the source record.
Quoted from the source exactly as published.
These preclinical findings suggest a plausible mechanism by which lupin protein hydrolysate may mitigate MASLD through NRF2-dependent antioxidant pathways. However, no human efficacy data, optimal dosing, or safety profile are provided; clinical translation requires formal human trials.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The rising prevalence of obesity and its comorbidities, including metabolic dysfunction–associated steatotic liver disease (MASLD), requires novel preventive strategies, such as functional foods. Lupinus angustifolius protein hydrolysates (LPH) exhibits potent immunomodulatory and antioxidant properties, underscoring their potential to mitigate metabolic dysfunction. This study evaluated the effects of LPH on a diet-induced obese mouse model of MASLD. LPH supplementation significantly reduced body and liver weight, attenuated hepatic steatosis, and normalized lipid accumulation and triglyceride levels. Furthermore, LPH enhanced antioxidant capacity by upregulating Nrf2 and increasing SOD, GPx, and CAT activities. LPH also modified the liver transcriptome towards an anti-obesogenic profile, modulating genes involved in lipid metabolism (e.g., Cd36 and Ldlr ), adipokine signaling, and oxidative stress. Interestingly, proteomic and in silico approaches identified bioactive peptides with predicted potential to target the NRF2-KEAP1 axis, providing a plausible mechanistic hypothesis. Collectively, these findings support the therapeutic potential of LPH in the context of MASLD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.